Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab
2023/02/09 by Yuemeng Wu, Chaoying Gu, Shangshang Wang +7 · 22 citations
Medicine · Immunology and Microbiology · #Dermatology and Skin Diseases #Asthma and respiratory diseases #Psoriasis: Treatment and Pathogenesis
paper · doi:10.1093/bjd/ljad032
Abstract
BACKGROUND: Atopic dermatitis (AD) is a highly heterogeneous disease clinically and biologically. Serum biomarkers have been utilized for endotype identification and have the potential to be predictors for treatment. OBJECTIVES: To explore the serum biomarker-based endotypes of Chinese patients with AD and to identify biomarkers for prediction of the efficacy of dupilumab. METHODS: Sera from 125 patients with moderate-to-severe AD and 60 normal controls (NC) were analysed for 24 cytokines/chemokines using the magnetic Luminex assay. After the patients received 16 weeks of dupilumab treatment, the efficacy was evaluated, and blood eosinophils, serum immunoglobulin (Ig) E and biomarkers were measured. RESULTS: Chinese patients with moderate-to-severe AD were characterized by T-helper (Th)2-dominant serum biomarkers that were mixed with differentially increased Th1-, Th17- and Th22-type cytokines/chemokines, and it was mainly Th2-type serum biomarkers that were positively correlated with disease severity and eosinophil counts. Adult (but not adolescent or elderly) patients with AD showed a consistent and more significant increase of biomarkers across different types of inflammation. The patients were grouped into two clusters by unsupervised k-means analysis, which were differentially associated with inflammation. Treatment with dupilumab decreased the levels of most cytokines/chemokines analysed. While there was no difference between the two clusters in the efficacy of dupilumab, baseline levels of CD25/soluble interleukin (sIL)-2Rα, IL-31 and IL-36β were identified as predictive factors associated with the efficacy. CONCLUSIONS: Our study revealed two inflammation-related endotypes of Chinese patients with AD based on serum biomarkers. High levels of CD25/sIL-2Rα, IL-31 and IL-36β might predict good efficacy of dupilumab treatment.
Cited by
- Blood Single-Cell Transcriptomic and Proteomic Signatures of Paradoxical Eczema in Patients with Psoriasis Treated with Biologics
- Assessment of Treatment-Relevant Immune Biomarkers in Psoriasis and Atopic Dermatitis: Toward Personalized Medicine in Dermatology. [europepmc]
- Increased Interleukin-36β Expression Promotes Angiogenesis in Japanese Atopic Dermatitis. [europepmc]
- Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types. [europepmc]
- Burden of Disease; the Current Status of the Diagnosis and Management of Atopic Dermatitis in China. [europepmc]
- Exploring the Potential of IL-4 and IL-13 Plasma Levels as Biomarkers in Atopic Dermatitis. [europepmc]
- The Efficacy and Effectiveness of the Biological Treatment of Pruritus in the Course of Atopic Dermatitis. [europepmc]
- Neural Biomarkers for Identifying Atopic Dermatitis and Assessing Acupuncture Treatment Response Using Resting-State fMRI. [europepmc]
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe? [europepmc]
- Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients. [europepmc]
- Atopic Dermatitis Immune Dysregulation as Dengue Predisposing Factor. [europepmc]
- Effects of Huang-Lian-Jie-Du decoction on improving skin barrier function and modulating T helper cell differentiation in 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis mice. [europepmc]
- The Association of Inflammatory Indexes Derived from Peripheral Blood Cell Count and Clinical Signs with Response to Treatment with Dupilumab in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis. [europepmc]
- Real-World Efficacy and Safety of Dupilumab Use in Japanese Adult Patients with Atopic Dermatitis: A Single-Center, Retrospective, 104-Week, Observational Study. [europepmc]
- Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives. [europepmc]
- Predictors for the Efficacy of 4-Week Dupilumab Treatment in Atopic Dermatitis Patients. [europepmc]
- A multidimensional analysis of prognostic factors in atopic dermatitis. [europepmc]
- Evaluation of the levels of interleukins IL-4, IL-13, IL-5, IL-10 and IL-33 in atopic dermatitis patients with and without dupilumab therapy. [europepmc]
- A Cost-Effective Screening Inflammation Indicator for Atopic Dermatitis Suitable for Primary Care and Self-Assessment. [europepmc]
- The Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy. [europepmc]
- Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review. [europepmc]
- Efficacy, Safety and Immunomodulatory Effect of Intramuscular Injections of Autologous Whole Blood Into Acupoints in Patients With Atopic Dermatitis: A Randomized Controlled Trial. [europepmc]
Related